ARIAD’s $5.2 Billion Merger with Takeda

Simpson Thacher is representing J.P. Morgan Securities LLC as financial advisor to ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) in connection with its definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) in a tender offer and merger transaction.

The transaction is expected to close in the first quarter of 2017, subject to regulatory approvals and customary closing conditions.

ARIAD is headquartered in Cambridge, Massachusetts and focuses on discovering, developing and commercializing precision therapies for patients with rare cancers. Takeda is a global, research and development-driven pharmaceutical company that focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines.

The Simpson Thacher team includes Caroline Gottschalk (Picture), Rob Spatt and Erika Tang (M&A).

Jones Day is acting as special counsel to Takeda Pharmaceuticals in its $5.2 billion acquisition of Ariad Pharmaceuticals with a team led by Dale Rieger.

Involved fees earner: Caroline Gottschalk – Simpson Thacher & Bartlett; Robert Spatt – Simpson Thacher & Bartlett; Erika Tang – Simpson Thacher & Bartlett; Dale Rieger – Jones Day;

Law Firms: Simpson Thacher & Bartlett; Jones Day;

Clients: JP Morgan Securities; Takeda;

Print Friendly, PDF & Email

Author: Ambrogio Visconti